tiprankstipranks
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksStock ScreenerCompare StocksPenny Stock ScreenerTop Product Insights Stocks
Daily Updates
Daily Analyst RatingsTrending StocksTop Stock GainersTop Stock LosersMost Active StocksDividend StocksChatGPT Stocks
New
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
ETF Research Tools
ETF CenterETF ScreenerTop ETFs by Smart Score
New
Compare ETFsTop ETFs by AUM
ETFs On the Move
Top ETF GainersTop ETF LosersMost Active ETFs
ETF Ideas
S&P 500 Index ETFsNasdaq 100 Index ETFsS&P 500 Sector ETFsBond ETFsCommodity ETFsCurrency ETFsIndustry ETFs
Best Dividend StocksBest High Yield Dividend StocksDividend Aristocrats
New
Dividend Stock ComparisonDividend Calculator
Popular
Dividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
My PortfolioMy WatchlistMy PerformanceMy Portfolio AnalysisCrowd Insights
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
Education
TipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityCareersContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Options Profit Calculator
New
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETF Research Tools
ETF Center
ETF Screener
New
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto Center
Bitcoin
Ethereum
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing

PCVX Stock Latest News

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
Press ReleasesVaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
24d ago
PCVX
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Press ReleasesVaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
1M ago
PCVX
Vaxcyte 11.2M share Secondary priced at $41.00
The FlyVaxcyte 11.2M share Secondary priced at $41.00
1M ago
PCVX
Vaxcyte Announces Pricing of $500 Million Public Offering
Press ReleasesVaxcyte Announces Pricing of $500 Million Public Offering
1M ago
PCVX
Vaxcyte initiated with an Outperform at TD Cowen
The FlyVaxcyte initiated with an Outperform at TD Cowen
1M ago
PCVX
Vaxcyte price target raised to $68 from $63 at BofA
The FlyVaxcyte price target raised to $68 from $63 at BofA
1M ago
PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Press ReleasesVaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
1M ago
PCVX
Vaxcyte announces offering of common stock, warrants
The FlyVaxcyte announces offering of common stock, warrants
1M ago
PCVX
New Vaccine Data Sends Vaxcyte Stock Blasting Up
Market NewsNew Vaccine Data Sends Vaxcyte Stock Blasting Up
1M ago
PFE
PCVX
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
Press ReleasesVaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
2M ago
PCVX
Vaxcyte reports ‘positive’ results from Phase 2 study of VAX-24
The FlyVaxcyte reports ‘positive’ results from Phase 2 study of VAX-24
2M ago
PCVX
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
Press ReleasesVaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
2M ago
PCVX
Vaxcyte doses first participants in Phase 2 study of VAX-24
The FlyVaxcyte doses first participants in Phase 2 study of VAX-24
2M ago
PCVX
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Press ReleasesVaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
2M ago
PCVX
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Press ReleasesVaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3M ago
PCVX
Vaxcyte announces FDA clearance of IND for VAX-24
The FlyVaxcyte announces FDA clearance of IND for VAX-24
3M ago
PCVX
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Press ReleasesVaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
3M ago
PCVX
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
Press ReleasesVaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
3M ago
PCVX
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
Press ReleasesVaxcyte to Present at the SVB Securities Global Biopharma Conference
4M ago
PCVX
Vaxcyte’s VAX-24 granted FDA Breakthrough Therapy designation
The FlyVaxcyte’s VAX-24 granted FDA Breakthrough Therapy designation
5M ago
PCVX
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
Press ReleasesVaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
5M ago
PCVX
Vaxcyte named as Top Pick, added to Conviction list at Needham
The FlyVaxcyte named as Top Pick, added to Conviction list at Needham
5M ago
PFE
APLS